{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:06:14Z","timestamp":1793739974762,"version":"4.6.1"},"reference-count":131,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MIRNA"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Non-alcoholic fatty liver disease (NAFLD) is commonly related to metabolic-associated\nchronic liver disease, which has a pathological spectrum from simple steatosis to non-alcoholic\nsteatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). It is\nmainly associated with other disease conditions, such as obesity, type 2 diabetes mellitus\n(T2DM), and cardiovascular disease. MicroRNAs (miRs) are small non-coding RNAs, having 22\nnucleotides in length, that play an important role in epigenetic modulation for disease. miRs act\nby targeting mRNA and altering its expression. Alteration of miRs regulates different stages of\nNAFLD and NASH. A liver biopsy is the gold standard diagnosis for NASH. However, it is an\ninvasive diagnostic process, so it is not feasible to screen a large number of NASH patients. Consequently,\nit is imperative to develop new non-invasive diagnosis strategies to detect NAFLD to\nNASH progression. Circulating miR can be a novel diagnostic marker for NAFLD\/NASH. This\nreview explains the role of miRs in the pathogenesis and miR-based targeted therapy in\nNAFLD\/NASH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0122115366364599250604050335","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T07:57:32Z","timestamp":1750233452000},"page":"199-213","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["MicroRNA: A Novel Class of Potential Biomarkers and Therapeutic Target for Non-Alcoholic Fatty Liver Disease\/Nonalcoholic Steatohepatitis"],"prefix":"10.2174","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2509-8788","authenticated-orcid":true,"given":"Indrajit","family":"Bhattacharya","sequence":"first","affiliation":[{"name":"Department of Pharmacology &amp; Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Chunilal Bhawan, 168 Maniktala Main Road, Kolkata 700054, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2096-2552","authenticated-orcid":true,"given":"Somasundaram","family":"Arumugam","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Chunilal Bhawan, 168 Maniktala Main Road, Kolkata 700054, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep","family":"Kumar Maity","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Chunilal Bhawan, 168 Maniktala Main Road, Kolkata 700054, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Chunilal Bhawan, 168 Maniktala Main Road, Kolkata 700054, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9477-2085","authenticated-orcid":true,"given":"Teeshyo","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Chunilal Bhawan, 168 Maniktala Main Road, Kolkata 700054, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5037-7593","authenticated-orcid":true,"given":"Amrita","family":"Sahu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Chunilal Bhawan, 168 Maniktala Main Road, Kolkata 700054, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remya","family":"Sreedhar","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sister Nivedita University,DG Block, 1\/2, Action Area I, Newtown, Kolkata 700156, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.4103\/ijcm.ijcm_437_22","volume":"48","author":"Anton M.C.","year":"2023","unstructured":"Anton M.C.; Shanthi B.; Sridevi C.; Prevalence of non-alcoholic fatty liver disease in urban adult population in a tertiary care center. Indian J Community Med  2023,48(4),601-604","journal-title":"Indian J Community Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.3390\/ijms20092215","volume":"20","author":"El Hadi H.","year":"2019","unstructured":"El Hadi H.; Di Vincenzo A.; Vettor R.; Rossato M.; Cardio-metabolic disorders in non-alcoholic fatty liver disease. Int J Mol Sci  2019,20(9),2215","journal-title":"Int J Mol Sci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"603926","DOI":"10.3389\/fphar.2020.603926","volume":"11","author":"Peng C.","year":"2020","unstructured":"Peng C.; Stewart A.G.; Woodman O.L.; Ritchie R.H.; Qin C.X.; Non-alcoholic steatohepatitis: A review of its mechanism, models and medical treatments. Front Pharmacol  2020,11,603926","journal-title":"Front Pharmacol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1021\/acsptsci.4c00185","volume":"7","author":"Yan B.","year":"2024","unstructured":"Yan B.; Zheng X.; Chen X.; Silibinin targeting heat shock protein 90 represents a novel approach to alleviate nonalcoholic fatty liver disease by simultaneously lowering hepatic lipotoxicity and enhancing gut barrier function. ACS Pharmacol Transl Sci  2024,7(7),2110-2124","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3390\/cells12101434","volume":"12","author":"Kakiyama G.","year":"2023","unstructured":"Kakiyama G.; Rodriguez-Agudo D.; Pandak W.M.; Mitochondrial cholesterol metabolites in a bile acid synthetic pathway drive nonalcoholic fatty liver disease: A revised \u201cTwo-Hit\u201d hypothesis. Cells  2023,12(10),1434","journal-title":"Cells"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.gendis.2021.12.013","volume":"10","author":"Wang Y.D.","year":"2023","unstructured":"Wang Y.D.; Wu L.L.; Qi X.Y.; New insight of obesity-associated NAFLD: Dysregulated \u201ccrosstalk\u201d between multi-organ and the liver? Genes Dis  2023,10(3),799-812","journal-title":"Genes Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.31518","volume":"73","author":"Tilg H.","year":"2021","unstructured":"Tilg H.; Adolph T.E.; Moschen A.R.; Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: Revisited after a decade. Hepatology  2021,73(2),833-842","journal-title":"Hepatology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"113869","DOI":"10.1016\/j.addr.2021.113869","volume":"176","author":"Kumar S.","year":"2021","unstructured":"Kumar S.; Duan Q.; Wu R.; Harris E.N.; Su Q.; Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis. Adv Drug Deliv Rev  2021,176,113869","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/cells9041041","volume":"9","author":"Lin H.Y.","year":"2020","unstructured":"Lin H.Y.; Yang Y.L.; Wang P.W.; Wang F.S.; Huang Y.H.; The emerging role of microRNAS in NAFLD: Highlight of microrna-29a in modulating oxidative stress, inflammation, and beyond. Cells  2020,9(4),1041","journal-title":"Cells"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"100485","DOI":"10.1016\/j.jlr.2023.100485","volume":"65","author":"Rinella M.E.","year":"2024","unstructured":"Rinella M.E.; Sookoian S.; From NAFLD to MASLD: Updated naming and diagnosis criteria for fatty liver disease. J Lipid Res  2024,65(1),100485","journal-title":"J Lipid Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"105127","DOI":"10.1016\/j.ebiom.2024.105127","volume":"103","author":"Hateley C.","year":"2024","unstructured":"Hateley C.; Olona A.; Halliday L.; Multi-tissue profiling of oxylipins reveal a conserved up-regulation of epoxide:diol ratio that associates with white adipose tissue inflammation and liver steatosis in obesity. EBioMedicine  2024,103,105127","journal-title":"EBioMedicine"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"154809","DOI":"10.1016\/j.prp.2023.154809","volume":"251","author":"Ramezani M.","year":"2023","unstructured":"Ramezani M.; Zobeiry M.; Abdolahi S.; Hatami B.; Zali M.R.; Baghaei K.; A crosstalk between epigenetic modulations and non-alcoholic fatty liver disease progression. Pathol Res Pract  2023,251,154809","journal-title":"Pathol Res Pract"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2174\/1389557523666230130093512","volume":"23","author":"Rivera-Aguirre J.","year":"2023","unstructured":"Rivera-Aguirre J.; L\u00f3pez-S\u00e1nchez G.N.; Ch\u00e1vez-Tapia N.C.; Uribe M.; Nu\u00f1o-L\u00e1mbarri N.; Metabolic-associated fatty liver disease regulation through nutri epigenetic methylation. Mini Rev Med Chem  2023,23(17),1680-1690","journal-title":"Mini Rev Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41580-024-00805-0","volume":"26","author":"Kim H.","year":"2024","unstructured":"Kim H.; Lee Y.Y.; Kim V.N.; The biogenesis and regulation of animal microRNAs. Nat Rev Mol Cell Biol  2024,26,276-296","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1321232","DOI":"10.3389\/fgene.2024.1321232","volume":"15","author":"Mohamed F.A.","year":"2024","unstructured":"Mohamed F.A.; Freude K.; Implications of SNP-triggered miRNA dysregulation in Schizophrenia development. Front Genet  2024,15,1321232","journal-title":"Front Genet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s42764-024-00135-7","volume":"5","author":"Malakondaiah S.","year":"2024","unstructured":"Malakondaiah S.; Julius A.; Ponnambalam D.; Gene silencing by RNA interference: A review. Genome Instab Disease  2024,5(5),225-241","journal-title":"Genome Instab Disease"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3390\/diseases12060121","volume":"12","author":"Nazou E.","year":"2024","unstructured":"Nazou E.; Potiris A.; Mavrogianni D.; Oocyte maturation and miRNAs: Studying a complicate interaction to reveal possible biomarkers for female infertility. Diseases  2024,12(6),121","journal-title":"Diseases"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-1-4939-7046-9_4","volume":"1617","author":"Huang W.","year":"2017","unstructured":"Huang W.; MicroRNAs: Biomarkers, diagnostics, and therapeutics. Methods Mol Biol  2017,1617,57-67","journal-title":"Methods Mol Biol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/wrna.1295","volume":"6","author":"Liu W.","year":"2015","unstructured":"Liu W.; Cao H.; Yan J.; Huang R.; Ying H.; \u2018Micro\u2010managers\u2019 of hepatic lipid metabolism and NAFLD. Wiley Interdiscip Rev RNA  2015,6(5),581-593","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/ijms20020298","volume":"20","author":"Chao H.W.","year":"2019","unstructured":"Chao H.W.; Chao S.W.; Lin H.; Ku H.C.; Cheng C.F.; Homeostasis of glucose and lipid in non-alcoholic fatty liver disease. Int J Mol Sci  2019,20(2),298","journal-title":"Int J Mol Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2300631","DOI":"10.1002\/ardp.202300631","volume":"357","author":"Samy A.M.","year":"2024","unstructured":"Samy A.M.; Kandeil M.A.; Sabry D.; Abdel-Ghany A.A.; Mahmoud M.O.; Exosomal miR\u2010122, miR\u2010128, miR\u2010200, miR\u2010298, and miR\u2010342 as novel diagnostic biomarkers in NAFL\/NASH: Impact of LPS\/TLR\u20104\/FoxO3 pathway. Arch Pharm  2024,357(4),2300631","journal-title":"Arch Pharm"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/liv.15682","volume":"43","author":"Rodrigues P.M.","year":"2023","unstructured":"Rodrigues P.M.; Afonso M.B.; Sim\u00e3o A.L.; miR \u201021\u20105p promotes NASH \u2010related hepatocarcinogenesis. Liver Int  2023,43(10),2256-2274","journal-title":"Liver Int"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fmed.2020.00007","volume":"7","author":"Zhang T.","year":"2020","unstructured":"Zhang T.; Yang Z.; Kusumanchi P.; Han S.; Liangpunsakul S.; Critical Role of microRNA-21 in the Pathogenesis of Liver Diseases. Front Med  2020,7,7","journal-title":"Front Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1136\/gutjnl-2015-310044","volume":"65","author":"Benhamouche-Trouillet S.","year":"2016","unstructured":"Benhamouche-Trouillet S.; Postic C.; Emerging role of miR-21 in non-alcoholic fatty liver disease. Gut  2016,65(11),1781-1783","journal-title":"Gut"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12864-018-4575-3","volume":"19","author":"Liu J.","year":"2018","unstructured":"Liu J.; Xiao Y.; Wu X.; A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis. BMC Genomics  2018,19(1),188","journal-title":"BMC Genomics"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.3892\/ijmm.2019.4375","volume":"44","author":"Wang X.M.","year":"2019","unstructured":"Wang X.M.; Wang X.Y.; Huang Y.M.; Role and mechanisms of action of microRNA 21 as regards the regulation of the WNT\/\u03b2 catenin signaling pathway in the pathogenesis of non alcoholic fatty liver disease. Int J Mol Med  2019,44(6),2201-2212","journal-title":"Int J Mol Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1136\/gutjnl-2015-310822","volume":"65","author":"Calo N.","year":"2016","unstructured":"Calo N.; Ramadori P.; Sobolewski C.; Stress-activated miR-21\/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. Gut  2016,65(11),1871-1881","journal-title":"Gut"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/13813455.2022.2046106","volume":"130","author":"BinMowyna MN","year":"2024","unstructured":"BinMowyna MN; AlFaris NA; Al-Sanea EA; AlTamimi JZ; Aldayel TS; Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a\/SIRT1 axis. Arch Physiol Biochem  2024,130(3),300-315","journal-title":"Arch Physiol Biochem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s10528-024-10754-0","volume":"63","author":"Bahramirad Z.","year":"2024","unstructured":"Bahramirad Z.; Moloudi M.R.; Moradzad M.; Abdollahi A.; Vahabzadeh Z.; Trimethylamine-N-oxide, a new risk factor for non-alcoholic fatty liver disease changes the expression of miRNA-34a, and miRNA-122 in the Fatty Liver Cell Model. Biochem Genet  2024,63(2),1298-1309","journal-title":"Biochem Genet"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.1038\/ncomms8466","volume":"6","author":"Xu Y.","year":"2015","unstructured":"Xu Y.; Zalzala M.; Xu J.; Li Y.; Yin L.; Zhang Y.; A metabolic stress-inducible miR-34a-HNF4\u03b1 pathway regulates lipid and lipoprotein metabolism. Nat Commun  2015,6(1),7466","journal-title":"Nat Commun"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"116854","DOI":"10.1016\/j.biopha.2024.116854","volume":"176","author":"Ali B.M.","year":"2024","unstructured":"Ali B.M.; Al-Mokaddem A.K.; Selim H.M.R.M.; Pinocembrin\u2019s protective effect against acute pancreatitis in a rat model: The correlation between TLR4\/NF-\u03baB\/NLRP3 and miR-34a-5p\/SIRT1\/Nrf2\/HO-1 pathways. Biomed Pharmacother  2024,176,116854","journal-title":"Biomed Pharmacother"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.2147\/DMSO.S437865","volume":"16","author":"Meng D.","year":"2023","unstructured":"Meng D.; Zhang F.; Yu W.; Biological role and related natural products of sirt1 in nonalcoholic fatty liver. Diabetes Metab Syndr Obes  2023,16,4043-4064","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"13729","DOI":"10.1038\/srep13729","volume":"5","author":"Ding J.","year":"2015","unstructured":"Ding J.; Li M.; Wan X.; Effect of miR-34a in regulating steatosis by targeting PPAR\u03b1 expression in nonalcoholic fatty liver disease. Sci Rep  2015,5(1),13729","journal-title":"Sci Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1752-0509-3-31","volume":"3","author":"Smith J.J.","year":"2009","unstructured":"Smith J.J.; Kenney R.D.; Gagne D.J.; Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst Biol  2009,3(1),31","journal-title":"BMC Syst Biol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jhep.2008.01.019","volume":"48","author":"Girard M.","year":"2008","unstructured":"Girard M.; Jacquemin E.; Munnich A.; Lyonnet S.; Henrion-Caude A.; miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol  2008,48(4),648-656","journal-title":"J Hepatol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1111\/liv.12429","volume":"34","author":"Miyaaki H.","year":"2014","unstructured":"Miyaaki H.; Ichikawa T.; Kamo Y.; Significance of serum and hepatic micro RNA \u2010122 levels in patients with non\u2010alcoholic fatty liver disease. Liver Int  2014,34(7),e302-e307","journal-title":"Liver Int"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1053\/j.gastro.2017.08.013","volume":"153","author":"Chai C.","year":"2017","unstructured":"Chai C.; Rivkin M.; Berkovits L.; Metabolic circuit involving free fatty acids, microrna 122, and triglyceride synthesis in liver and muscle tissues. Gastroenterology  2017,153(5),1404-1415","journal-title":"Gastroenterology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/obr.12765","volume":"20","author":"Baranova A.","year":"2019","unstructured":"Baranova A.; Maltseva D.; Tonevitsky A.; Adipose may actively delay progression of NAFLD by releasing tumor\u2010suppressing, anti\u2010fibrotic miR \u2010122 into circulation. Obes Rev  2019,20(1),108-118","journal-title":"Obes Rev"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1136\/gutjnl-2018-318146","volume":"68","author":"Gjorgjieva M.","year":"2019","unstructured":"Gjorgjieva M.; Sobolewski C.; Dolicka D.; Correia de Sousa M.; Foti M.; miRNAs and NAFLD: From pathophysiology to therapy. Gut  2019,68(11),2065-2079","journal-title":"Gut"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1194\/jlr.M071357","volume":"58","author":"Natarajan S.K.","year":"2017","unstructured":"Natarajan S.K.; Stringham B.A.; Mohr A.M.; FoxO3 increases miR-34a to cause palmitate-induced cholangiocyte lipoapoptosis. J Lipid Res  2017,58(5),866-875","journal-title":"J Lipid Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"Gorrini C.","year":"2013","unstructured":"Gorrini C.; Harris I.S.; Mak T.W.; Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov  2013,12(12),931-947","journal-title":"Nat Rev Drug Discov"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/livers2040023","volume":"2","author":"Conde de la Rosa L.","year":"2022","unstructured":"Conde de la Rosa L.; Role of oxidative stress in liver disorders. Livers  2022,2(4),283-314","journal-title":"Livers"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jhep.2021.01.042","volume":"75","author":"Liu C.","year":"2021","unstructured":"Liu C.; Zhou B.; Meng M.; FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease. J Hepatol  2021,75(1),150-162","journal-title":"J Hepatol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1172\/JCI75438","volume":"125","author":"Fu X.","year":"2015","unstructured":"Fu X.; Dong B.; Tian Y.; MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. J Clin Invest  2015,125(6),2497-2509","journal-title":"J Clin Invest"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/hep.31428","volume":"73","author":"Xu H.","year":"2021","unstructured":"Xu H.; Tian Y.; Tang D.; An endoplasmic reticulum stress\u2013microRNA\u201026a feedback circuit in NAFLD. Hepatology  2021,73(4),1327-1345","journal-title":"Hepatology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.bbrc.2016.04.065","volume":"474","author":"Cheng Y.","year":"2016","unstructured":"Cheng Y.; Mai J.; Hou T.; Ping J.; MicroRNA-421 induces hepatic mitochondrial dysfunction in non-alcoholic fatty liver disease mice by inhibiting sirtuin 3. Biochem Biophys Res Commun  2016,474(1),57-63","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1515\/hsz-2017-0303","volume":"399","author":"Wang X.","year":"2018","unstructured":"Wang X.; Wang J.; High-content hydrogen water-induced downregulation of miR-136 alleviates non-alcoholic fatty liver disease by regulating Nrf2 via targeting MEG3. Biol Chem  2018,399(4),397-406","journal-title":"Biol Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.18632\/aging.102721","volume":"12","author":"Zhang Y.","year":"2020","unstructured":"Zhang Y.; Wang C.; Lu J.; Targeting of miR-96-5p by catalpol ameliorates oxidative stress and hepatic steatosis in LDLr-\/- mice via p66shc\/cytochrome C cascade. Aging  2020,12(3),2049-2069","journal-title":"Aging"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2174\/138161210791208875","volume":"16","author":"Bugianesi E.","year":"2010","unstructured":"Bugianesi E.; Moscatiello S.; Ciaravella M.F.; Marchesini G.; Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des  2010,16(17),1941-1951","journal-title":"Curr Pharm Des"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"Buzzetti E.","year":"2016","unstructured":"Buzzetti E.; Pinzani M.; Tsochatzis E.A.; The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism  2016,65(8),1038-1048","journal-title":"Metabolism"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"C588","DOI":"10.1152\/ajpcell.00253.2022","volume":"324","author":"Atic A.I.","year":"2023","unstructured":"Atic A.I.; Circulating miRNAs associated with nonalcoholic fatty liver disease. Am J Physiol Cell Physiol  2023,324(2),C588-C602","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"14978","DOI":"10.18632\/aging.103557","volume":"12","author":"Xu Y.","year":"2020","unstructured":"Xu Y.; Yu T.; He L.; Inhibition of miRNA-152-3p enhances diabetic wound repair via upregulation of PTEN. Aging  2020,12(14),14978-14989","journal-title":"Aging"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/21691401.2018.1453830","volume":"846","author":"He S","year":"2018","unstructured":"He S; Targeted delivery of microRNA 146b mimic to hepatocytes by lactosylated PDMAEMA nanoparticles for the treatment of NAFLD. Artif Cells Nanomed Biotechnol  2018,846(sup2),217-228","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/febs.13713","volume":"283","author":"Wang S.","year":"2016","unstructured":"Wang S.; Wang L.; Dou L.; Micro RNA 152 regulates hepatic glycogenesis by targeting PTEN. FEBS J  2016,283(10),1935-1946","journal-title":"FEBS J"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.7150\/ijbs.59588","volume":"17","author":"Fang Z.","year":"2021","unstructured":"Fang Z.; Dou G.; Wang L.; MicroRNAs in the pathogenesis of nonalcoholic fatty liver disease. Int J Biol Sci  2021,17(7),1851-1863","journal-title":"Int J Biol Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1159\/000430198","volume":"36","author":"Wang L.","year":"2015","unstructured":"Wang L.; Zhang N.; Pan H.; Wang Z.; Cao Z.; MiR-499-5p contributes to hepatic insulin resistance by suppressing PTEN. Cell Physiol Biochem  2015,36(6),2357-2365","journal-title":"Cell Physiol Biochem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1002\/mnfr.201500107","volume":"59","author":"Yang W.M.","year":"2015","unstructured":"Yang W.M.; Jeong H.J.; Park S.W.; Lee W.; Obesity\u2010induced miR\u201015b is linked causally to the development of insulin resistance through the repression of the insulin receptor in hepatocytes. Mol Nutr Food Res  2015,59(11),2303-2314","journal-title":"Mol Nutr Food Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1111\/liv.14067","volume":"39","author":"Dai L.L.","year":"2019","unstructured":"Dai L.L.; Li S.D.; Ma Y.C.; MicroRNA\u201030b regulates insulin sensitivity by targeting SERCA2b in non\u2010alcoholic fatty liver disease. Liver Int  2019,39(8),1504-1513","journal-title":"Liver Int"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jhep.2016.12.016","volume":"66","author":"Wu H.","year":"2017","unstructured":"Wu H.; Zhang T.; Pan F.; MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis. J Hepatol  2017,66(4),816-824","journal-title":"J Hepatol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.1002\/jcb.26776","volume":"119","author":"Xu M.","year":"2018","unstructured":"Xu M.; Zheng X.M.; Jiang F.; Qiu W.; MicroRNA\u2010190b regulates lipid metabolism and insulin sensitivity by targeting IGF\u20101 and ADAMTS9 in non\u2010alcoholic fatty liver disease. J Cell Biochem  2018,119(7),5864-5874","journal-title":"J Cell Biochem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41392-022-00974-4","volume":"7","author":"Hou K.","year":"2022","unstructured":"Hou K.; Wu Z.X.; Chen X.Y.; Microbiota in health and diseases. Signal Transduct Target Ther  2022,7(1),135","journal-title":"Signal Transduct Target Ther"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"997018","DOI":"10.3389\/fcimb.2022.997018","volume":"12","author":"Fang J.","year":"2022","unstructured":"Fang J.; Yu C.H.; Li X.J.; Gut dysbiosis in nonalcoholic fatty liver disease: Pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol  2022,12,997018","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s11845-023-03529-w","volume":"193","author":"Huang S.","year":"2024","unstructured":"Huang S.; Xiao X.; Wu H.; Zhou F.; Fu C.; MicroRNA-582-3p knockdown alleviates non-alcoholic steatohepatitis by altering the gut microbiota composition and moderating TMBIM1. Ir J Med Sci  2024,193(2),909-916","journal-title":"Ir J Med Sci"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"104996","DOI":"10.1016\/j.ebiom.2024.104996","volume":"101","author":"Pirola C.J.","year":"2024","unstructured":"Pirola C.J.; Salatino A.; Fern\u00e1ndez Gianotti T.; Casta\u00f1o G.O.; Garaycoechea M.; Sookoian S.; Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver disease. EBioMedicine  2024,101,104996","journal-title":"EBioMedicine"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/3927134","volume":"2018","author":"Feng D.","year":"2018","unstructured":"Feng D.; Mukhopadhyay P.; Qiu J.; Wang H.; Inflammation in liver diseases. Mediators Inflamm  2018,2018,1-2","journal-title":"Mediators Inflamm"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s00018-016-2161-x","volume":"73","author":"Liu W.","year":"2016","unstructured":"Liu W.; Baker R.D.; Bhatia T.; Zhu L.; Baker S.S.; Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci  2016,73(10),1969-1987","journal-title":"Cell Mol Life Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"Schuster S.","year":"2018","unstructured":"Schuster S.; Cabrera D.; Arrese M.; Feldstein A.E.; Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol  2018,15(6),349-364","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","volume":"76","author":"Bessone F.","year":"2019","unstructured":"Bessone F.; Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci  2019,76(1),99-128","journal-title":"Cell Mol Life Sci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0153-7","volume":"50","author":"Ye D.","year":"2018","unstructured":"Ye D.; Zhang T.; Lou G.; Liu Y.; Role of miR-223 in the pathophysiology of liver diseases. Exp Mol Med  2018,50(9),1-12","journal-title":"Exp Mol Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/hep.30645","volume":"70","author":"He Y.","year":"2019","unstructured":"He Y.; Hwang S.; Cai Y.; MicroRNA\u2010223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes. Hepatology  2019,70(4),1150-1167","journal-title":"Hepatology"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/hep.31658","volume":"74","author":"Hou X.","year":"2021","unstructured":"Hou X.; Yin S.; Ren R.; Myeloid\u2010cell\u2013specific IL\u20106 signaling promotes microRNA\u2010223\u2010enriched exosome production to attenuate nafld\u2010associated fibrosis. Hepatology  2021,74(1),116-132","journal-title":"Hepatology"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"100212","DOI":"10.1016\/j.aohep.2020.04.012","volume":"21","author":"L\u00f3pez-S\u00e1nchez G.N.","year":"2021","unstructured":"L\u00f3pez-S\u00e1nchez G.N.; D\u00f3minguez-P\u00e9rez M.; Uribe M.; Ch\u00e1vez-Tapia N.C.; Nu\u00f1o-L\u00e1mbarri N.; Non-alcoholic fatty liver disease and microRNAs expression, how it affects the development and progression of the disease. Ann Hepatol  2021,21,100212","journal-title":"Ann Hepatol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.3390\/nu7053483","volume":"7","author":"Tian H.","year":"2015","unstructured":"Tian H.; Liu C.; Zou X.; Wu W.; Zhang C.; Yuan D.; MiRNA-194 regulates palmitic acid-induced toll-like receptor 4 inflammatory responses in THP-1 cells. Nutrients  2015,7(5),3483-3496","journal-title":"Nutrients"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"154375","DOI":"10.1016\/j.prp.2023.154375","volume":"243","author":"Doghish A.S.","year":"2023","unstructured":"Doghish A.S.; Elballal M.S.; Elazazy O.; The role of miRNAs in liver diseases: Potential therapeutic and clinical applications. Pathol Res Pract  2023,243,154375","journal-title":"Pathol Res Pract"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.31050","volume":"72","author":"Liu X.L.","year":"2020","unstructured":"Liu X.L.; Pan Q.; Cao H.X.; Lipotoxic hepatocyte\u2010derived exosomal microRNA 192\u20105p activates macrophages through rictor\/akt\/forkhead box transcription factor o1 signaling in nonalcoholic fatty liver disease. Hepatology  2020,72(2),454-469","journal-title":"Hepatology"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jhep.2018.08.026","volume":"70","author":"Zhang T.","year":"2019","unstructured":"Zhang T.; Hu J.; Wang X.; MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-\u03baB-TNF\u03b1 pathway. J Hepatol  2019,70(1),87-96","journal-title":"J Hepatol"},{"key":"ref=77","first-page":"200","volume":"12","author":"Karimi-Sales E.","year":"2022","unstructured":"Karimi-Sales E.; Jeddi S.; Ebrahimi-Kalan A.; Alipour M.R.; Protective role of trans-chalcone against the progression from simple steatosis to non-alcoholic steatohepatitis: Regulation of miR-122, 21, 34a, and 451. Adv Pharm Bull  2022,12(1),200-205","journal-title":"Adv Pharm Bull"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41575-018-0065-y","volume":"15","author":"Schwabe R.F.","year":"2018","unstructured":"Schwabe R.F.; Luedde T.; Apoptosis and necroptosis in the liver: A matter of life and death. Nat Rev Gastroenterol Hepatol  2018,15(12),738-752","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.3748\/wjg.v24.i25.2661","volume":"24","author":"Kanda T.","year":"2018","unstructured":"Kanda T.; Matsuoka S.; Yamazaki M.; Apoptosis and non-alcoholic fatty liver diseases. World J Gastroenterol  2018,24(25),2661-2672","journal-title":"World J Gastroenterol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1016\/j.ajpath.2015.08.020","volume":"185","author":"Qadir X.V.","year":"2015","unstructured":"Qadir X.V.; Chen W.; Han C.; Song K.; Zhang J.; Wu T.; miR-223 Deficiency protects against fas-induced hepatocyte apoptosis and liver injury through targeting insulin-like growth factor 1 receptor. Am J Pathol  2015,185(12),3141-3151","journal-title":"Am J Pathol"},{"key":"ref=81","first-page":"4925","volume":"9","author":"Feng Z.","year":"2017","unstructured":"Feng Z.; Li Z.; Zhu D.; Mir-24 regulates hepatocyte apoptosis via BIM during acute liver failure. Am J Transl Res  2017,9(11),4925-4935","journal-title":"Am J Transl Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3892\/mmr.2020.11123","volume":"22","author":"Wu S.","year":"2020","unstructured":"Wu S.; Huang X.; Sun W.; Role of the microRNA 214\/Bax axis in the progression of acute liver failure. Mol Med Rep  2020,22(1),117-126","journal-title":"Mol Med Rep"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0168-8278(02)00429-4","volume":"38","author":"Friedman S.L.","year":"2003","unstructured":"Friedman S.L.; Liver fibrosis \u2013 from bench to bedside. J Hepatol  2003,38(Suppl. 1),38-53","journal-title":"J Hepatol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1055\/s-0035-1550065","volume":"35","author":"Angulo P.","year":"2015","unstructured":"Angulo P.; Machado M.; Diehl A.; Fibrosis in nonalcoholic fatty liver disease: Mechanisms and clinical implications. Semin Liver Dis  2015,35(2),132-145","journal-title":"Semin Liver Dis"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","volume":"68","author":"Schuppan D.","year":"2018","unstructured":"Schuppan D.; Surabattula R.; Wang X.Y.; Determinants of fibrosis progression and regression in NASH. J Hepatol  2018,68(2),238-250","journal-title":"J Hepatol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.3390\/ijms19123966","volume":"19","author":"Dongiovanni P.","year":"2018","unstructured":"Dongiovanni P.; Meroni M.; Longo M.; Fargion S.; Fracanzani A.L.; miRNA signature in NAFLD: A turning point for a non-invasive diagnosis. Int J Mol Sci  2018,19(12),3966","journal-title":"Int J Mol Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.trsl.2015.04.014","volume":"166","author":"Leti F.","year":"2015","unstructured":"Leti F.; Malenica I.; Doshi M.; High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease\u2013related fibrosis. Transl Res  2015,166(3),304-314","journal-title":"Transl Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"G298","DOI":"10.1152\/ajpgi.00346.2014","volume":"308","author":"Dattaroy D.","year":"2015","unstructured":"Dattaroy D.; Pourhoseini S.; Das S.; Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol  2015,308(4),G298-G312","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/hep.29627","volume":"67","author":"Caviglia J.M.","year":"2018","unstructured":"Caviglia J.M.; Yan J.; Jang M.K.; MicroRNA\u201021 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology  2018,67(6),2414-2429","journal-title":"Hepatology"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/liv.12633","volume":"35","author":"Csak T.","year":"2015","unstructured":"Csak T.; Bala S.; Lippai D.; micro RNA \u2010122 regulates hypoxia\u2010inducible factor\u20101 and vimentin in hepatocytes and correlates with fibrosis in diet\u2010induced steatohepatitis. Liver Int  2015,35(2),532-541","journal-title":"Liver Int"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"16163","DOI":"10.1038\/srep16163","volume":"5","author":"Du J.","year":"2015","unstructured":"Du J.; Niu X.; Wang Y.; MiR-146a-5p suppresses activation and proliferation of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis through directly targeting Wnt1 and Wnt5a. Sci Rep  2015,5(1),16163","journal-title":"Sci Rep"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"G39","DOI":"10.1152\/ajpgi.00263.2007","volume":"294","author":"Cheng J.H.","year":"2008","unstructured":"Cheng J.H.; She H.; Han Y.P.; Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol  2008,294(1),G39-G49","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41419-018-0752-1","volume":"9","author":"Ma L.","year":"2018","unstructured":"Ma L.; Yang X.; Wei R.; MicroRNA-214 promotes hepatic stellate cell activation and liver fibrosis by suppressing Sufu expression. Cell Death Dis  2018,9(7),718","journal-title":"Cell Death Dis"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/cas.12730","volume":"106","author":"Okada H.","year":"2015","unstructured":"Okada H.; Honda M.; Campbell J.S.; Inhibition of micro RNA \u2010214 ameliorates hepatic fibrosis and tumor incidence in platelet\u2010derived growth factor C transgenic mice. Cancer Sci  2015,106(9),1143-1152","journal-title":"Cancer Sci"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1038\/cddis.2017.10","volume":"8","author":"Wang Y.","year":"2017","unstructured":"Wang Y.; Du J.; Niu X.; MiR-130a-3p attenuates activation and induces apoptosis of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis by directly targeting TGFBR1 and TGFBR2. Cell Death Dis  2017,8(5),2792","journal-title":"Cell Death Dis"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jhep.2018.12.016","volume":"70","author":"Tsay H.C.","year":"2019","unstructured":"Tsay H.C.; Yuan Q.; Balakrishnan A.; Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis. J Hepatol  2019,70(4),722-734","journal-title":"J Hepatol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"101581","DOI":"10.1016\/j.molmet.2022.101581","volume":"65","author":"Hochreuter M.Y.","year":"2022","unstructured":"Hochreuter M.Y.; Dall M.; Treebak J.T.; Barr\u00e8s R.; MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives. Mol Metab  2022,65,101581","journal-title":"Mol Metab"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jhep.2018.08.008","volume":"69","author":"Liu C.H.","year":"2018","unstructured":"Liu C.H.; Ampuero J.; Gil-G\u00f3mez A.; miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol  2018,69(6),1335-1348","journal-title":"J Hepatol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0109298673276581231210170332","author":"Yang J.","year":"2024","unstructured":"Yang J.; Tang X.; Chen L.; Liver-derived exosomal miRNA in NAFLD: Mechanisms of action, biomarkers, and therapeutic applications. Curr Med Chem  2024,1-8","journal-title":"Curr Med Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12876-020-01334-8","volume":"20","author":"Xin S.","year":"2020","unstructured":"Xin S.; Zhan Q.; Chen X.; Xu J.; Yu Y.; Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: A systematic review and meta-analysis. BMC Gastroenterol  2020,20(1),186","journal-title":"BMC Gastroenterol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40290-019-00305-z","volume":"33","author":"Albhaisi S.","year":"2019","unstructured":"Albhaisi S.; Sanyal A.J.; Applying non-invasive fibrosis measurements in nafld\/nash: Progress to date. Pharmaceut Med  2019,33(6),451-463","journal-title":"Pharmaceut Med"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1038\/s41598-025-87791-1","volume":"15","author":"Zhang J.W.","year":"2025","unstructured":"Zhang J.W.; Ullah K.; Khan N.; Pan H.T.; Comprehensive profiling of serum microRNAs in normal and non-alcoholic fatty liver disease (NAFLD) patients. Sci Rep  2025,15(1),3766","journal-title":"Sci Rep"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3748\/wjg.v30.i4.332","volume":"30","author":"Li Y.J.","year":"2024","unstructured":"Li Y.J.; Baumert B.O.; Stratakis N.; Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity. World J Gastroenterol  2024,30(4),332-345","journal-title":"World J Gastroenterol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3390\/biomedicines13010230","volume":"13","author":"Michalak A.","year":"2025","unstructured":"Michalak A.; Guz M.; Kozicka J.; miRNAs and hematological markers in non-alcoholic fatty liver disease\u2014a new diagnostic path? Biomedicines  2025,13(1),230","journal-title":"Biomedicines"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/2211536607666180531093302","volume":"7","author":"Jampoka K.","year":"2018","unstructured":"Jampoka K.; Muangpaisarn P.; Khongnomnan K.; Treeprasertsuk S.; Tangkijvanich P.; Payungporn S.; Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD). MicroRNA  2018,7(3),215-222","journal-title":"MicroRNA"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"4221368","DOI":"10.1155\/2024\/4221368","volume":"2024","author":"Sutradhar P.R.","year":"2024","unstructured":"Sutradhar P.R.; Sultana N.; Nessa A.; miRNA\u2010221: A Potential biomarker of progressive liver injury in chronic liver disease (CLD) due to hepatitis b virus (HBV) and nonalcoholic fatty liver disease (NAFLD). Int J Hepatol  2024,2024(1),4221368","journal-title":"Int J Hepatol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"101964","DOI":"10.1016\/j.genrep.2024.101964","volume":"36","author":"Amani F.","year":"2024","unstructured":"Amani F.; Sahebkar A.; Aghaee-Bakhtiari S.H.; Farzanehfar M.; Askarian S.; Oskuee R.K.; Evaluation of the diagnostic role of circulating miR-16, miR-10b, and miR-21 expression in patients with nonalcoholic fatty liver disease. Gene Rep  2024,36,101964","journal-title":"Gene Rep"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13105-024-01037-8","author":"Tobaruela-Resola A.L.","year":"2024","unstructured":"Tobaruela-Resola A.L.; Milagro F.I.; Elorz M.; Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessment. J Physiol Biochem  2024,1-9","journal-title":"J Physiol Biochem"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s43141-023-00467-z","volume":"21","author":"Ragab H.M.","year":"2023","unstructured":"Ragab H.M.; Ezzat W.M.; Hassan E.M.; Significance of MiRNA-34a and MiRNA-192 as a risk factor for nonalcoholic fatty liver disease. J Genet Eng Biotechnol  2023,21(1),13","journal-title":"J Genet Eng Biotechnol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s43141-021-00257-5","volume":"19","author":"Mohamed A.A.","year":"2021","unstructured":"Mohamed A.A.; El-Demery A.; Al-Hussain E.; NAFLD mark: An accurate model based on microRNA-34 for diagnosis of non-alcoholic fatty liver disease patients. J Genet Eng Biotechnol  2021,19(1),157","journal-title":"J Genet Eng Biotechnol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"18856","DOI":"10.1038\/s41598-019-55076-z","volume":"9","author":"Ando Y.","year":"2019","unstructured":"Ando Y.; Yamazaki M.; Yamada H.; Association of circulating miR-20a, miR-27a, and miR-126 with non-alcoholic fatty liver disease in general population. Sci Rep  2019,9(1),18856","journal-title":"Sci Rep"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"e3045","DOI":"10.1038\/cddis.2017.440","volume":"8","author":"Hamam R.","year":"2017","unstructured":"Hamam R.; Hamam D.; Alsaleh K.A.; Circulating microRNAs in breast cancer: Novel diagnostic and prognostic biomarkers. Cell Death Dis  2017,8(9),e3045-e5","journal-title":"Cell Death Dis"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-10-2010","volume":"70","author":"Bader A.G.","year":"2010","unstructured":"Bader A.G.; Brown D.; Winkler M.; The promise of microRNA replacement therapy. Cancer Res  2010,70(18),7027-7030","journal-title":"Cancer Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12890-019-0836-4","volume":"19","author":"Zhang W.","year":"2019","unstructured":"Zhang W.; Jia J.; Liu Z.; Si D.; Ma L.; Zhang G.; Circulating microRNAs as biomarkers for Sepsis secondary to pneumonia diagnosed via Sepsis 3.0. BMC Pulm Med  2019,19(1),93","journal-title":"BMC Pulm Med"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"BSR20181722","DOI":"10.1042\/BSR20181722","volume":"39","author":"Jun L.","year":"2019","unstructured":"Jun L.; Tang T.T.; Tao T.J.B.R.; LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a\/PPAR\u03b3 axis in non-alcoholic fatty liver disease. Biosci Rep  2019,39(7),BSR20181722","journal-title":"Biosci Rep"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"110190","DOI":"10.1016\/j.cellsig.2021.110190","volume":"90","author":"Guo B.","year":"2022","unstructured":"Guo B.; LncRNA HOTAIR regulates the lipid accumulation in non-alcoholic fatty liver disease via miR-130b-3p\/ROCK1 axis. Cell Sig  2022,90,110190","journal-title":"Cell Sig"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"e2748","DOI":"10.1038\/cddis.2017.172","volume":"8","author":"Rodrigues P.M.","year":"2017","unstructured":"Rodrigues P.M.; miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. Cell Death Dis  2017,8(4),e2748","journal-title":"Cell Death Dis"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.bbrc.2020.01.143","volume":"524","author":"Zhang M.","year":"2020","unstructured":"Zhang M.; MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1. Biochem Biophys Res Commun  2020,524(3),716-722","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"e0144295","DOI":"10.1371\/journal.pone.0144295","volume":"10","author":"Nakamura M.","year":"2015","unstructured":"Nakamura M.; MicroRNA-122 inhibits the production of inflammatory cytokines by targeting the PKR activator PACT in human hepatic stellate cells. PLoS One  2015,10(12),e0144295","journal-title":"PLoS One"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/gutjnl-2020-322526","volume":"70","author":"Wang X.","year":"2021","unstructured":"Wang X.; He Y.; Mackowiak B.; Gao B.; MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut  2021,70(4),784-795","journal-title":"Gut"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.immuni.2020.05.003","volume":"52","author":"Gao Y.","year":"2020","unstructured":"Gao Y.; Vasic R.; Song Y.; m6A modification prevents formation of endogenous double-stranded RNAs and deleterious innate immune responses during hematopoietic development. Immunity  2020,52(6),1007-1021.e8","journal-title":"Immunity"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"176955","DOI":"10.1016\/j.ejphar.2024.176955","volume":"982","author":"Yang Y.L.","year":"2024","unstructured":"Yang Y.L.; Chuang Y.T.; Huang Y.H.; MicroRNA 29a alleviates mitochondrial stress in diet-induced NAFLD by inhibiting the MAVS pathway. Eur J Pharmacol  2024,982,176955","journal-title":"Eur J Pharmacol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"116829","DOI":"10.1016\/j.lfs.2019.116829","volume":"235","author":"Chen X.","year":"2019","unstructured":"Chen X.; Tan X.R.; Li S.J.; Zhang X.X.; LncRNA NEAT1 promotes hepatic lipid accumulation via regulating miR-146a-5p\/ROCK1 in nonalcoholic fatty liver disease. Life Sci  2019,235,116829","journal-title":"Life Sci"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nature04303","volume":"438","author":"Kr\u00fctzfeldt J.","year":"2005","unstructured":"Kr\u00fctzfeldt J.; Rajewsky N.; Braich R.; Silencing of microRNAs in vivo with \u2018antagomirs\u2019. Nature  2005,438(7068),685-689","journal-title":"Nature"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/ng.786","volume":"43","author":"Obad S.","year":"2011","unstructured":"Obad S.; dos Santos C.O.; Petri A.; Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet  2011,43(4),371-378","journal-title":"Nat Genet"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.addr.2017.12.011","volume":"129","author":"Meng Z.","year":"2018","unstructured":"Meng Z.; Zhou D.; Gao Y.; Zeng M.; Wang W.; miRNA delivery for skin wound healing. Adv Drug Deliv Rev  2018,129,308-318","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1021\/acs.jafc.9b04259","volume":"68","author":"Wu W.Y.","year":"2020","unstructured":"Wu W.Y.; Ding X.Q.; Gu T.T.; Pterostilbene improves hepatic lipid accumulation via the MiR-34a\/Sirt1\/SREBP-1 pathway in fructose-fed rats. J Agric Food Chem  2020,68(5),1436-1446","journal-title":"J Agric Food Chem"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2174\/13894501113149990191","volume":"14","author":"Wang R.","year":"2013","unstructured":"Wang R.; Ma J.; Wu Q.; Functional role of miR-34 family in human cancer. Curr Drug Targets  2013,14(10),1185-1191","journal-title":"Curr Drug Targets"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"6868","DOI":"10.18632\/aging.205730","volume":"16","author":"Du G.","year":"2024","unstructured":"Du G.; Jiang Z.; Xia T.; lincRNA00907 promotes NASH progression by targeting miRNA-942-5p\/TAOK1. Aging  2024,16(8),6868-6882","journal-title":"Aging"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"640587","DOI":"10.3389\/fcell.2021.640587","volume":"9","author":"Li W.J.","year":"2021","unstructured":"Li W.J.; Wang Y.; Liu R.; MicroRNA-34a: Potent tumor suppressor, cancer stem cell inhibitor, and potential anticancer therapeutic. Front Cell Dev Biol  2021,9,640587","journal-title":"Front Cell Dev Biol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.actbio.2023.04.002","volume":"164","author":"Kong M.","year":"2023","unstructured":"Kong M.; Peng Y.; Qiu L.; Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR\/miR-34a\/SIRT1 regulatory loop. Acta Biomater  2023,164,435-446","journal-title":"Acta Biomater"}],"container-title":["MicroRNA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0122115366364599250604050335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/242730\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0122115366364599250604050335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T04:38:47Z","timestamp":1765427927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/242730\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":131,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0122115366364599250604050335","relation":{},"ISSN":["2211-5366"],"issn-type":[{"value":"2211-5366","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}